| Literature DB >> 25652366 |
Suguru Saito1, Toshihiko Kawamura2, Masaya Higuchi1, Takahiro Kobayashi2, Manami Yoshita-Takahashi1,3, Maya Yamazaki4, Manabu Abe4, Kenji Sakimura4, Yasuhiro Kanda2, Hiroki Kawamura5, Shuying Jiang6,7, Makoto Naito6, Takumi Yoshizaki1, Masahiko Takahashi1, Masahiro Fujii1.
Abstract
Ras GTPase-activating proteins negatively regulate the Ras/Erk signaling pathway, thereby playing crucial roles in the proliferation, function, and development of various types of cells. In this study, we identified a novel Ras GTPase-activating proteins protein, RASAL3, which is predominantly expressed in cells of hematopoietic lineages, including NKT, B, and T cells. We established systemic RASAL3-deficient mice, and the mice exhibited a severe decrease in NKT cells in the liver at 8 weeks of age. The treatment of RASAL3-deficient mice with α-GalCer, a specific agonist for NKT cells, induced liver damage, but the level was less severe than that in RASAL3-competent mice, and the attenuated liver damage was accompanied by a reduced production of interleukin-4 and interferon-γ from NKT cells. RASAL3-deficient NKT cells treated with α-GalCer in vitro presented augmented Erk phosphorylation, suggesting that there is dysregulated Ras signaling in the NKT cells of RASAL3-deficient mice. Taken together, these results suggest that RASAL3 plays an important role in the expansion and functions of NKT cells in the liver by negatively regulating Ras/Erk signaling, and might be a therapeutic target for NKT-associated diseases.Entities:
Keywords: IL-4; Liver injury; NKT cell; Ras; RasGAP; α-GalCer
Mesh:
Substances:
Year: 2015 PMID: 25652366 DOI: 10.1002/eji.201444977
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532